Group Pharmaceuticals Limited Unlisted Shares - Company Overview

Group Pharmaceuticals Limited is an unlisted public company incorporated on 24 July, 1980. It is classified as a public limited company and is located in Thane, Maharashtra. It's authorized share capital is INR 5.00 cr and the total paid-up capital is INR 2.54 cr.

Description: The company is engaged in pharmaceutical company. It develops niche oral care products with specific dental and oral conditions.

Products & Services: Group Dental Care Products, Group Denture Care, Group Oral Gels, Group Mouth Wash, Group Disinfectants,
Category: Manufacturer

Group Pharmaceuticals Limited Share Price, Share Details as of March 31, 2025

Group Pharmaceuticals Limited Incorporation Details

Group Pharmaceuticals Limited Board of Directors

Director	Post
Jacob Mathew	Director
Ann Valerie Sunil Attavar	Whole Time Director
Sunil Cajaten Attavar	Director
Deepak Mohan	Managing Director
Annasagaram Balagurunath Ramkumar	Whole Time Director
Nandipur Kallappa Dilip	Director

FAQs on Group Pharmaceuticals Ltd

Q: What is the face value of Group Pharmaceuticals Ltd shares?
Answer: The face value of Group Pharmaceuticals Ltd is ₹10 per equity share.

Q: What is the minimum lot size for buying Group Pharmaceuticals shares through WWIPL?
Answer: The minimum lot size is typically 100 shares, depending on availability in the unlisted market.

Q: How can I buy Group Pharmaceuticals unlisted shares through WWIPL?
Answer: Investors complete KYC, confirm trade details with WWIPL, transfer funds, and receive shares in their Demat account after settlement.

Q: Why should I buy Group Pharmaceuticals shares through WWIPL?
Answer: WWIPL provides access to unlisted shares with assisted execution, transparent pricing, secure settlement, and Demat transfer support.

Q: Is investing in Group Pharmaceuticals Ltd a good idea?
Answer: Group Pharmaceuticals is a 40+ year old pharmaceutical manufacturing company focused on oral care and specialty healthcare products, with improving operational performance and export presence, but it remains a mid-scale unlisted pharma business with limited liquidity and moderate visibility compared to large listed peers.

Q: Why do investors buy Group Pharmaceuticals shares before listing?
Answer: Investors typically expect value re-rating from steady pharma operations, niche oral-care specialization, export exposure, and potential listing-driven liquidity unlock.

Q: What business does Group Pharmaceuticals Ltd operate in?
Answer: The company is engaged in pharmaceutical manufacturing, especially oral care products (toothpaste, mouthwash, dental care solutions) and healthcare formulations, with exports to multiple global markets.

Q: What makes Group Pharmaceuticals different from other unlisted pharma companies?
Answer: It is relatively niche-focused in oral healthcare, with a strong product specialization (dental/oral care segment) rather than a broad generic pharmaceutical portfolio like large pharma players.

Q: What are the key growth drivers for Group Pharmaceuticals Ltd?
Answer: Growth depends on expansion in oral-care demand, export scaling, new product innovation, contract manufacturing opportunities, and distribution expansion across geographies.

Q: What factors affect the valuation of Group Pharmaceuticals shares?
Answer: Valuation is driven by revenue growth, margin expansion, export performance, product pipeline strength, and liquidity in the unlisted market, along with overall pharma sector sentiment.

Q: Are Group Pharmaceuticals shares available in Demat form?
Answer: Yes. Shares are held in dematerialized form (NSDL/CDSL) and can be transferred between Demat accounts.

Q: Can I sell my Group Pharmaceuticals shares through WWIPL?
Answer: Yes, but liquidity is limited and depends on buyer availability in the unlisted market.

Q: What documents are required to buy Group Pharmaceuticals shares through WWIPL?
Answer: PAN, Aadhaar, Client Master Report (CMR), and bank details are typically required.

Q: What are the risks of investing in Group Pharmaceuticals shares?
Answer: Key risks include low liquidity, mid-scale operations, competition from larger pharma companies, and dependency on niche product demand cycles.

Q: How long does it take for shares to be credited to a Demat account?
Answer: Credit typically occurs after trade settlement and counterparty confirmation, depending on market liquidity.

Q: What should investors evaluate before investing in Group Pharmaceuticals Ltd?
Answer: Investors should assess product concentration in oral care, export dependency, margin stability, and long-term scalability of manufacturing operations.

Q: Can Group Pharmaceuticals benefit from pharma industry growth?
Answer: Yes, especially from growing oral-care demand and global healthcare consumption, but sustained upside depends on its ability to scale beyond niche positioning.